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Preterm birth refers to delivery before 37 completed weeks of gestation. Its prevalence is increasing the worldwide and more than one in 10 babies are born preterm annually. 
The survival of preterm infants has greatly improved due to 
advances in neonatology. Significant neonatal complications 
are directly related to the gestational age at delivery and include 
chronic lung disease, intraventricular hemorrhage (IVH), and 
periventricular white matter disease; the latter two can result 
in cerebral palsy (CP) and neurodevelopmental delay. Antenatal 
corticosteroids, surfactant therapy, and gentle ventilation 
have reduced the respiratory complications of prematurity 
significantly [1].
In several observational studies, antenatal administration of 
magnesium sulfate (MgSO4) for tocolysis or pre-eclampsia has 
been associated with a reduction in neonatal mortality and CP in 
low birth weight children [2,3]; however, these beneficial effects 
were not observed in other similar studies [4-6]. The beneficial 
effect of MgSO4 in prevention of CP was first noted in a case–
control study [7], where the incidence of CP in preterm babies 
was significantly reduced by exposure to antenatal MgSO4 when 
compared to control subjects who did not receive the same (odds 
ratio [OR]: 0.14; 95% confidence interval [CI]: 0.05-0.51). It 
was postulated that in the vulnerable preterm brain, MgSO4 may 
reduce vascular instability, prevent hypoxic damage, and reduce 
cytokine or excitatory amino acid damage [8].
Three randomized trials were undertaken in recent years in 
Australia and New Zealand, France, and the United States, to 
assess the effectiveness of MgSO4 in reducing neonatal mortality, 
perinatal cerebral injuries and/or CP [9-11]. The results of the 
first trial, conducted by the Australasian Collaborative Trial of the 
MgSO4 Collaborative Group showed short-term neuroprotective 
effects as well as significantly lower rate of major gross motor 
dysfunction at 2 years in children born preterm (<30 weeks 
of gestation) whose mothers had been given prenatal MgSO4 
infusions rather than placebo saline infusions [9].
While several western countries have formulated guidelines 
on the use of MgSO4 as a neuroprotective agent, there are very 
few Indian studies regarding the antenatal use of MgSO4 as a 
neuroprotective agent [12]. MgSO4 is inexpensive and commonly 
used in the management of pre-eclampsia and for tocolysis. We 
undertook this study to test the hypothesis that antenatal MgSO4 
has a neuroprotective role in the early neonatal period, when 
given to women considered at risk for preterm delivery.
MATERIALS AND METHODS
Study Design and Participants
We conducted an open label randomized controlled trial in a 
tertiary care teaching hospital in India from February 1, 2014 
ABSTRACT
Objective: To test the hypothesis that antenatal magnesium sulfate (MgSO4) has a short term neuroprotective role in the early 
neonatal period, when given to women considered at risk for preterm delivery in a developing country. Study Design: Randomized, 
placebo-controlled, open label, trial. Participants: A total of 126 mothers who delivered at or below 34 weeks gestation were 
randomized to receive either antenatal MgSO4 (cases) or normal saline as placebo (controls). A total of 108 babies born were 
observed for the primary and secondary outcomes. Primary Outcome: The composite of the incidence of death and intraventricular 
hemorrhage (IVH) by cranial ultrasonography in surviving preterm infants. Results: There were 6 deaths in cases and 11 deaths in 
controls (relative risk [RR]: 0.54; 95% confidence interval [CI]: 0.2173-1.369; p=0.18). A statistically significant reduction in the 
number of IVH was observed in cases (n=1) compared to controls (n=9) (RR: 0.11; 95% CI: 0.0145-0.897; p=0.016) with a number 
needed to treat of 7. Conclusion: Antenatal MgSO4 resulted in a significant reduction in the risk of IVH in preterm infants born at 
or below 34 weeks of gestation.
Key words: Antenatal magnesium sulfate, Intraventricular hemorrhage, Neuroprotection, Preterm infants
Vol 4 | Issue 2 | Apr - Jun 2017 Indian J Child Health 200
Varanattu et al. Antenatal magnesium sulphate for neuroprotection of prematurity
to November 30, 2015. Pregnant women with singleton, twin, 
or triplet fetuses between 24 and 34 weeks of gestational age 
were eligible for recruitment if birth was expected or planned 
within 24 h. Exclusion criteria include fetus with severe 
malformations or chromosomal abnormalities, maternal 
hypotension, cardiac rhythm or electrolyte abnormalities, renal 
or hepatic insufficiency, maternal contraindications to MgSO4, 
unwillingness of the obstetrician to intervene for fetal benefit, 
and receipt of MgSO4 within the previous 12 h. The duration 
of gestation was calculated at an entry to the trial according 
to a previously described algorithm [13] that makes use of the 
date of the last menstrual period (if reliable) and the results of 
the earliest available ultrasonogram. The study was approved 
officially by the Institutional Research Committee and Ethical 
Review Board. All participants gave written informed consent 
before enrolment.
Procedure
Eligible, consenting women were randomly assigned to receive 
either intravenous MgSO4 (a 4 g bolus followed by a constant 
infusion of 1 g/h for 24 h or until birth, whichever comes first) 
or matching placebo (normal saline). The study was single 
blinded, and allocation was concealed by sequentially numbered 
opaque sealed envelopes, in which the treatment for next person 
recruited for the study was mentioned, and the intervention was 
not concealed from the patients. If delivery did not occur after 
24 h and was no longer considered imminent (e.g., if the woman 
was not having regular uterine contractions), the infusion was 
discontinued. Imminent preterm birth was defined as a high 
likelihood of birth, due to one or both of the following conditions: 
Active labor with ≥4 cm of cervical dilation with or without 
preterm premature rupture of membranes and planned preterm 
birth for fetal or maternal indications.
Preterm babies born to eligible women were recruited into 
the study and assigned to one of the two groups depending on 
whether their mothers received MgSO4 or not. Members of the 
investigating team collected information regarding the mother’s 
demographic features, medical history, and social history at 
the time of enrolment in the study. The members also obtained 
data about maternal and neonatal outcomes at delivery. During 
admission to the neonatal intensive care unit, clinical assessment 
of neurological status was done by the principal investigator 
(first author) and repeated daily until discharge. Apart from the 
detailed clinical examination, Hammersmith Short Neurological 
Evaluation Score was used for daily assessment of neurological 
status and the full version of the Hammersmith Neonatal 
Neurologic Assessment was used to evaluate the infants at the 
time of discharge and thereafter [14].
Neonatal cranial ultrasonography was performed on all 
neonates by a single radiologist specialized in neurosonography 
who was blinded to group allocation on day 0-3, day 7, and 
day 28 for assessment of IVH and classified as per Volpe’s 
classification [15].
Outcomes
The primary outcome was the composite incidence of the 
death and IVH by cranial ultrasonography in surviving 
preterm infants. Neonatal death until discharge was considered 
significant for the study. The secondary outcomes studied were 
resuscitation at birth, respiratory distress syndrome, surfactant 
administration, type and duration of ventilator support, hypoxic 
ischemic encephalopathy, apnea of prematurity, sepsis, anemia 
requiring transfusion, necrotizing enterocolitis, and patent 
ductus arteriosus. We estimated that the primary outcome would 
occur in 20% of the control group [9] and calculated the sample 
size, by Fleiss formula using OpenEpi software, version 3.03. 
Thus, a total sample of 134, equally divided into two groups 
was deemed sufficient for the detection of a 22% reduction in 
this outcome, with a Type I error (two-sided) of 5% and a power 
of at least 80%.
Statistical Analysis
All statistical analyses were calculated on an intention to treat 
basis to avoid overestimation of clinical effectiveness. The 
data from all patients were analyzed according to the group to 
which they were assigned randomly. Categorical variables were 
summarized as percentages and were analyzed by relative risk 
(RR) assessment. We performed analysis of the primary outcome 
and its components, excluding infants with major congenital 
anomalies noted at birth. Infants with blood culture proven or with 
definite clinical evidence of severe sepsis as the primary cause of 
death were also excluded from the study. Statistical analysis was 
performed using IBM SPSS Statistics 20.0 software. A p<0.05 
was considered statistically significant.
RESULTS
A total of 126 mothers were randomly assigned to treatment 
or placebo group. Of the 134 neonates born to these mothers 
(including 8 sets of twin pregnancy), 16 had to be excluded as 
shown in Fig. 1. Remaining 118 neonates were randomized into 
two groups and out of them, 108 eligible neonates were included 
in the final analysis. There were 54 cases and 54 controls in the 
study group of preterm infants as depicted in the participant 
flowchart (Fig. 1). No adverse events were observed in the 
mothers included in the study.
The baseline characteristics of the study population are 
displayed in Table 1, the primary outcome in Table 2 and the 
secondary outcome in Table 3. There were 6 deaths in cases 
and 11 deaths in controls (RR: 0.54; 95% CI: 0.2173-1.369; 
p=0.18). Two babies in the control group who died did not receive 
antenatal steroids. There was only one case of IVH (Grade 1) seen 
in the study group whereas there were four cases of Grade 1 IVH, 
three cases of Grade 2 IVH, and three cases of Grade 3 IVH seen 
in controls. There was no case of periventricular echodensity 
seen in both the groups (as per Volpe’s classification) [15]. 
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A statistically significant reduction in the number of IVH was 
observed in cases (n=1) compared to controls (n=9) (RR: 0.11; 
95% CI: 0.0145-0.897; p=0.016) with a number needed to treat 
of 7. One baby in the control group who did not receive antenatal 
steroids developed IVH.
DISCUSSION
We found that antenatal administration of MgSO4 in women at 
imminent risk for delivery between 24 and 34 weeks of gestation 
resulted in a significant reduction in the primary outcome of the 
IVH but not death. None of the cases developed a significant 
degree of IVH. Analysis of both primary and secondary outcomes 
ruled out any neonatal complications in the group that received 
antenatal MgSO4. The number of women needed to treat with 
MgSO4 to prevent IVH in one preterm infant is 7 and hence, highly 
significant for a prophylactic intervention. MgSO4 is inexpensive 
and commonly used in obstetric practice. Unlike corticosteroids, 
which need to be given at least 24 h before delivery to obtain a 
maximum beneficial effect, the window of opportunity for the 
administration of MgSO4 is shorter, about 4 h before birth.
Historically, the positive association between in utero 
exposure to MgSO4 and a reduction in perinatal morbidity was 
first reported by Kuban et al. in 1992 [16]. They conducted a 
prospective study of 449 babies delivered with birth weight 
<1501 g and found that maternal receipt of MgSO4 was associated 
with a decreased incidence of IVH. Petrova and Mehta in 2012 
studied 89 IVH cases and 89 controls that were comparable for 
parity, mode of delivery, antenatal exposure to corticosteroid, and 
surfactant administration. They found that among the IVH cases, 
30.3% of infants were exposed to tocolytic MgSO4 as compared 
to 47.2% of the controls (OR adjusted: 0.471; 95% CI: 0.241-
0.906), thereby suggesting that antenatal exposure to MgSO4 may 
have a protective effect against IVH [17].
The Cochrane review of MgSO4 for women at risk of 
preterm birth for neuroprotection of the fetus [18] showed no 
significant reduction in pediatric outcomes of IVH (RR: 0.96; 
95% CI: 0.86-1.08; four trials; 4552 infants). Subgroup analysis 
revealed that when MgSO4 was given with the intent for 
neuroprotection, the magnesium group compared with placebo, 
showed a significant decrease in the risk of death or CP (RR: 0.85; 
95% CI: 0.74-0.98; four trials; 4446 infants) and a significant 
decrease in substantial gross motor dysfunction (RR: 0.60; 
95% CI: 0.43-0.83; three trials; 4387 children). All the primary 
outcome variables of our study (death and IVH) were considered 
among the secondary outcomes in the Cochrane review. It is 
interesting to note that though the secondary outcomes were 
not significantly different between treatment groups, these were 
not always reported. Limitations of our study include relatively 
small sample size and a lack of double blinding and long-term 
follow-up. At present, Indian protocols do not recommend routine 
antenatal administration of MgSO4 to mothers at risk of preterm 
delivery. Like most experimental studies, the significance of our 
findings needs to be validated by conducting large multicenter 
trials with long-term follow-up so as to adapt the same in the 
routine management of mothers at risk of preterm labor.
Figure 1: Participant flowchart
Table 1: Baseline characteristics of the study population
Characteristic Cases Controls p value
Gestational age >0.99
<28 weeks 3 3
28-32 weeks 31 28
32-34 weeks 20 23
Sex 0.84
Male 32 33
Female 22 21
Antenatal steroids received 0.07
Complete 39 30
Incomplete 8 14
Nil 7 10
Mode of delivery 0.56
Vaginal 25 22
Cesarean 29 32
Birth weight 0.30
<1000 g 11 7
1000-1499 g 22 33
>1500 g 21 1
Table 2: Primary outcome
Characteristic Cases Controls RR 95% CI p value
Death 6 11 0.54 0.2173-1.369 0.18
IVH 1 9 0.11 0.0145-0.897 0.016
RR: Relative risk, CI: Confidence interval, IVH: Intra ventricular hemorrhage
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CONCLUSION
We conclude that antenatal MgSO4 resulted in a significant 
reduction in the risk of IVH and may be considered for the 
primary prevention of IVH in preterm infants of gestational 
age 34 weeks and below. The above treatment is cost-effective, 
without neonatal side effects and clinically significant for a 
prophylactic intervention.
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Table 3: Secondary outcome
Characteristic Cases Controls RR 95% CI p value
Resuscitation
Not required 24 22
PPV 9 12
Advanced resuscitation 3 2 1.5 0.261-8.622 >0.99
5’ APGAR<6 4 5 0.8 0.227-2.819 >0.99
RDS 51 49 1.04 0.935-1.158 0.71
Surfactant therapy 41 43 0.95 0.779-1.167 0.64
Ventilation
CPAP 43 44
Invasive ventilation 14 15 0.93 0.500-1.74 0.82
HIE 3 5 0.6 0.150-2.387 0.71
Apnea 17 15 1.13 0.632-2.33 0.67
Sepsis 13 10 1.3 0.624-2.706 0.48
Anemia requiring transfusion 9 8 1.12 0.469-2.69 0.79
NEC** stage 2 or more 6 5 1.2 0.389-3.69 0.75
PDA 4 6 0.66 0.199-2.23 0.50
PPV: Positive pressure ventilation, RDS: Respiratory distress syndrome, CPAP: Continuous positive airway pressure, HIE: Hypoxic ischemic encephalopathy, NEC: Necrotizing 
enterocolitis, PDA: Patent ductus arteriosus
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